47 results found.

B-cell Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, Rec Clinical Trial using fludarabine phosphate; rituximab; total-body irradiation; allogeneic hematopoietic stem cell transplantation; peripheral blood stem cell transplantation; cyclosporine; mycophenolate mofetil; laboratory biomarker analysis; pharmacological study

Fred Hutchinson Cancer Research Center - Recruiting 18 years or older.
- Nonmyeloablative Conditioning With Pre- and Post-Transplant Rituximab Followed by Related or Unrelated Donor Hematopoietic Cell Transplantation for Patients With Advanced Chronic Lymphocytic Leukemia: A Multi-Center Trial.
fludarabine phosphate; rituximab; total-body irradiation; allogeneic hematopoietic stem cell transplantation; peripheral blood stem cell transplantation; cyclosporine; mycophenolate mofetil; laboratory biomarker analysis; pharmacological study

Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Diffuse Large Clinical Trial using GS-9973

Gilead Sciences - Recruiting 18 years or older.
- A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Subjects With Relapsed or Refractory Hematologic Malignancies.
GS-9973

Glioblastoma Multiforme, Squamous Cell Carcinoma of Head and Neck Clinical Trial using CC-115

Celgene Corporation - Recruiting 18 years or older.
- A Phase 1a/b, Multicenter, Open Label, Dose-Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the Dual DNA-PK and TOR Kinase Inhibitor, CC-115, Administered Orally to Subjects With Advanced Solid Tumors, and Hematologic Malignancies..
CC-115

Leukemia, Lymphocytic, Chronic, B-Cell Clinical Trial using BI 836826

Boehringer Ingelheim - Recruiting 18 years or older.
- A Phase I, Open, Dose Escalation Trial With BI 836826 in Patients With Advanced Chronic Lymphocytic Leukaemia.
BI 836826

Lymphocytic Leukemia, Chronic, Lymphoma, B-Cell Clinical Trial using GDC-0853

Genentech - Recruiting 18 years or older.
- AN OPEN-LABEL, PHASE I, DOSE-ESCALATION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF GDC-0853 IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN'S LYMPHOMA AND CHRONIC LYMPHOCYTIC LEUKEMIA.
GDC-0853

Leukemia, Lymphoma, or Multiple Myeloma and Plasma Cell Neoplasm Clinical Trial using busulfan; cyclophosphamide; Stem cell infusion; Total body irradiation

Masonic Cancer Center, University of Minnesota - Recruiting N/A to 55 years.
- Unrelated or Partially Matched Allogeneic Donor Stem Cells for Lymphoma, Myeloma, and Chronic Lymphocytic Leukemia.
busulfan; cyclophosphamide; Stem cell infusion; Total body irradiation

Solid Tumor, Ovarian Cancer, Non-small Cell Lung Cancer, Chronic Clinical Trial

Cancer Centre of Monoclonal Therapy, LLC - Recruiting 18 years or older.
- Prognostic Potential of Cell Surface Markers and Pim Kinases in Patients With Selected Refractory or Relapsed Hematologic Malignancies or Solid Tumors.

B Cell Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, or W Clinical Trial using AVL-292

Celgene Corporation - Recruiting 18 years or older.
- Phase 1b, Escalating Dose Study of AVL-292, a Bruton's Tyrosine Kinase (Btk) Inhibitor, as Monotherapy in Subjects With Relapsed and/or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia.
AVL-292

Indolent Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, or Clinical Trial using Idelalisib; Rituximab; Bendamustine; Ofatumumab; Fludarabine; Everolimus; Bortezomib; Chlorambucil; Lenalidomide

Gilead Sciences - Recruiting 18 years or older.
- A Phase I Study to Investigate the Safety and Clinical Activity of Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 mAb in Subjects With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia.
Idelalisib; Rituximab; Bendamustine; Ofatumumab; Fludarabine; Everolimus; Bortezomib; Chlorambucil; Lenalidomide

Leukemia Clinical Trial using Busulfan; Clofarabine; Gemcitabine; Thymoglobulin; Allogeneic Stem Cell Transplantation; Filgrastim; Tacrolimus; Methotrexate

M.D. Anderson Cancer Center - Recruiting 18 years to 70 years.
- Clofarabine, Gemcitabine and Busulfan Followed by Allogeneic Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL).
Busulfan; Clofarabine; Gemcitabine; Thymoglobulin; Allogeneic Stem Cell Transplantation; Filgrastim; Tacrolimus; Methotrexate

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Clinical Trial using PCI-32765 (Ibrutinib)

Janssen Research & Development, LLC - Recruiting 18 years or older.
- A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study.
PCI-32765 (Ibrutinib)

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Clinical Trial using Anti-CD19-CAR Transduced PBL; Fludarabine; Cyclophosphamide; PG13-CD19-H3 (anti-CD19-CAR) transduced PBL)

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 68 years.
- Assessment of the Safety and Feasibility of Administering T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor to Patients With B-cell Lymphoma or Leukemia.
Anti-CD19-CAR Transduced PBL; Fludarabine; Cyclophosphamide; PG13-CD19-H3 (anti-CD19-CAR) transduced PBL)

Monoclonal B-Cell Lymphocytosis Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Study of the Kinetics of Lymphoid Cells in Patients With Monoclonal B-Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL), Mantle Cell Lymphoma (MCL) and Healthy Volunteers..

Hairy Cell Leukemia (HCL), Chronic Lymphocytic Leukemia (CLL), No Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Collection of Human Samples to Study Hairy Cell and Other Leukemias and to Develop Recombinant Immunotoxins for Cancer Treatment.

B-cell Chronic Lymphocytic Leukemia Clinical Trial using Lenalidomide; Placebo

Celgene Corporation - Recruiting 18 years or older.
- A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Efficacy and Safety of Lenalidomide (Revlimidr) as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia Following Second Line Therapy (THE CONTINUUM TRIAL).
Lenalidomide; Placebo

Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Clinical Trial using yttrium Y 90 anti-CD45 monoclonal antibody BC8; carmustine; etoposide; cytarabine; melphalan; peripheral blood stem cell transplantation; autologous hematopoietic stem cell transplantation; laboratory biomarker analysis

Fred Hutchinson Cancer Research Center - Recruiting 18 years or older.
- A Phase I/II Study Evaluating Escalating Doses of 90Y-BC8-DOTA (Anti-CD45) Antibody Followed by BEAM Chemotherapy and Autologous Stem Cell Transplantation for High-Risk Lymphoid Malignancies.
yttrium Y 90 anti-CD45 monoclonal antibody BC8; carmustine; etoposide; cytarabine; melphalan; peripheral blood stem cell transplantation; autologous hematopoietic stem cell transplantation; laboratory biomarker analysis

B-cell Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocyt Clinical Trial using alemtuzumab; rituximab; PGG beta-glucan; flow cytometry; laboratory biomarker analysis; DNA analysis; fluorescence in situ hybridization; polymerase chain reaction; polymorphism analysis; mutation analysis

Mayo Clinic - Recruiting 18 years or older.
- Early Treatment of High Risk Chronic Lymphocytic Leukemia With Alemtuzumab, Rituximab, and PGG Beta-Glucan: A Phase I/II Trial.
alemtuzumab; rituximab; PGG beta-glucan; flow cytometry; laboratory biomarker analysis; DNA analysis; fluorescence in situ hybridization; polymerase chain reaction; polymorphism analysis; mutation analysis

Lymphocytic Leukemia, Chronic Clinical Trial using rituximab [MabThera]; fludarabine; cyclophosphamide; chlorambucil

Hoffmann-La Roche - Recruiting 60 years or older.
- Prospective Randomized Study to Compare Efficacy and Safety of RFC-lite (Rituximab, Fludarabine, Cyclophosphamide) Regimen With LR (Rituximab, Chlorambucil) as a First-line Therapy in Patients With B-cell Chronic Lymphocytic Leukemia and Unfavorable Somatic Status.
rituximab [MabThera]; fludarabine; cyclophosphamide; chlorambucil

B-cell Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, Rec Clinical Trial using ofatumumab; dinaciclib; laboratory biomarker analysis; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase 1b/2 Study of Dinaciclib (SCH 727965) and Ofatumumab in Relapsed and Refractory CLL/SLL/B-PLL.
ofatumumab; dinaciclib; laboratory biomarker analysis; pharmacological study

B-cell Chronic Lymphocytic Leukemia, Cutaneous B-cell Non-Hodgkin Clinical Trial using ipilimumab; rituximab; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase I Study of Ipilimumab in Combination With Rituximab in Patients With Relapsed/Refractory CD20+ B-Cell Lymphoma.
ipilimumab; rituximab; laboratory biomarker analysis

Advanced Cancers, or Leukemia Clinical Trial using Leukapheresis; Fludarabine; Cyclophosphamide; T-cell Infusion

M.D. Anderson Cancer Center - Recruiting 18 years to 80 years.
- Autologous CD19 Specific T-cell Infusion in Patients With B-cell Chronic Lymphocytic Leukemia (B-CLL).
Leukapheresis; Fludarabine; Cyclophosphamide; T-cell Infusion

Leukemia, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Chr Clinical Trial using Fludarabine monophosphate; Busulfan; Stem Cell Infusion; Tacrolimus; Methotrexate; G-CSF

M.D. Anderson Cancer Center - Recruiting 5 years to 75 years.
- Randomized Phase II Study of Timed Sequential Busulfan in Combination With Fludarabine in Allogeneic Stem Cell Transplantation.
Fludarabine monophosphate; Busulfan; Stem Cell Infusion; Tacrolimus; Methotrexate; G-CSF

B-cell Chronic Lymphocytic Leukemia, Cutaneous B-cell Non-Hodgkin Clinical Trial using alisertib; romidepsin; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase 1 Trial of MLN8237 Plus Romidepsin for Relapsed/Refractory Aggressive B-Cell and T-Cell Lymphomas.
alisertib; romidepsin; laboratory biomarker analysis

Chronic Lymphocytic Leukemia, or Mantle Cell Lymphoma Clinical Trial using Ublituximab; Ibrutinib

TG Therapeutics, Inc. - Recruiting 18 years or older.
- A Multi-center Phase II Study With Safety Run-in Evaluating the Efficacy and Safety of Ublituximab in Combination With Ibrutinib in Patients With Select B-Cell Malignancies.
Ublituximab; Ibrutinib

Indolent Non-Hodgkin Lymphoma, Mantle Cell Lymphoma, or Chronic L Clinical Trial using SAR245409

Sanofi - Recruiting 18 years or older.
- A Phase 1b, Multicenter, Open-Label, Dose Escalation Study of SAR245409 to Evaluate the Safety, Tolerability and Clinical Activity of SAR245409 in Combination With Rituximab or Bendamustine Plus Rituximab in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia.
SAR245409

Acute Myelogenous Leukemia, Diffuse Large B-Cell Leukemia, Chroni Clinical Trial using BMS-936564 (Anti-CXCR4)

Bristol-Myers Squibb - Recruiting 18 years or older.
- A Phase 1, Open-label, Multicenter Study of BMS-936564 (MDX-1338) in Subjects With Relapsed Acute Myelogenous Leukemia and Selected B-cell Malignancies.
BMS-936564 (Anti-CXCR4)

Leukemia Clinical Trial using therapeutic autologous lymphocytes; cyclophosphamide

Memorial Sloan-Kettering Cancer Center - Recruiting 18 years or older.
- A Phase I/IIa Trial For The Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19.
therapeutic autologous lymphocytes; cyclophosphamide

Lymphocytic Leukemia, Chronic Clinical Trial using rituximab [MabThera]; fludarabine; cyclophosphamide

Hoffmann-La Roche - Recruiting 18 years to 70 years.
- Prospective Study of Efficacy and Safety of RFC (Rituximab, Fludarabine, Cyclophosphamide) Regimen as a First-Line Therapy in Patients With B-Cell Chronic Lymphocytic Leukemia and Favorable Somatic Status.
rituximab [MabThera]; fludarabine; cyclophosphamide

B-cell Chronic Lymphocytic Leukemia Clinical Trial using B-CLL Vaccine; Lenalidomide

Baylor College of Medicine - Recruiting 18 years to 75 years.
- Treatment of B-CLL With Autologous IL2 and CD40 Ligand-Expressing Tumor Cells + Lenalidomide.
B-CLL Vaccine; Lenalidomide

Lymphocytic Leukemia, Chronic Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- An Observational Phase IV Non Interventional Study Evaluating Further the Safety of Rituximab in Combination With Various Chemotherapies for the Treatment of Patients With CD20- Positive B-cell Chronic Lymphocytic Leukaemia in Greece.

Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Myelodysplasi Clinical Trial using Chemotherapy and antibodies; Miltenyi Biotec CliniMACS; Allogeneic stem cell transplantation

St. Jude Children's Research Hospital - Recruiting N/A to 24 Months.
- HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies.
Chemotherapy and antibodies; Miltenyi Biotec CliniMACS; Allogeneic stem cell transplantation

Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Clinical Trial using romidepsin; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase 1 and Pharmacokinetic Single Agent Study of Romidepsin in Patients With, Lymphomas, Chronic Lymphocytic Leukemia and Select Solid Tumors and Varying Degrees of Liver Dysfunction.
romidepsin; pharmacological study

Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymph Clinical Trial using bortezomib; filgrastim; autologous hematopoietic stem cell transplantation

Barbara Ann Karmanos Cancer Institute - Recruiting 18 years to 70 years.
- A Pilot Study of Peripheral Blood Hematopoietic Stem Cell Mobilization With the Combination of Bortezomib and G-CSF in Multiple Myeloma and Non-Hodgkin's Lymphoma Patients.
bortezomib; filgrastim; autologous hematopoietic stem cell transplantation

B-Cell Chronic Lymphocytic Leukemia, Monoclonal B-Cell Lymphocyto Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Natural History Study of Monoclonal B Cell Lymphocytosis (MBL) and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).

Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic M Clinical Trial using iTreg

Masonic Cancer Center, University of Minnesota - Recruiting 18 years to 75 years.
- Dose Escalation Study With Extension of Inducible Regulatory T Cells (iTregs) in Adult Patients Undergoing Non-Myeloablative HLA Identical Sibling Donor Peripheral Blood Stem Cell Transplantation.
iTreg

Leukemia Clinical Trial using cyclophosphamide; modified T cells

Memorial Sloan-Kettering Cancer Center - Recruiting 18 years or older.
- A Phase I Trial of Consolidation Therapy With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 in Patients With Chronic Lymphocytic Leukemia Following Upfront Chemotherapy With Pentostatin, Cyclophosphamide and Rituximab.
cyclophosphamide; modified T cells

Chronic Lymphocytic Leukemia (CLL) Clinical Trial using Autologous tumor cell extract vaccine

Xeme Biopharma Inc. - Recruiting 18 years or older.
- A Phase Ib Trial of Oncoquest-CLL Vaccine for Treatment-Naive Patients With Chronic Lymphocytic Leukemia.
Autologous tumor cell extract vaccine

Leukemia Lymphocytic Chronic B-Cell Clinical Trial using CC-292; Lenalidomide

Celgene Corporation - Recruiting 18 years or older.
- A Multicenter, Phase 1B, Open-Label Study to Determine the Safety and Activity of CC-292 in Combination With Lenalidomide in Subjects With Relapsed and /or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma.
CC-292; Lenalidomide

Lymphoma, Myeloma, or Leukemia Clinical Trial using Kappa CD28 T cells

Baylor College of Medicine - Recruiting 18 years or older.
- Phase I Study of Adoptive Transfer of Autologous T Lymphocytes Engrafted With a Chimeric Antigen Receptor Targeting the Kappa Light Chain of Immunoglobulin Expressed in Patients With Chronic Lymphocytic Leukemia, B-Cell Lymphoma or Multiple Myeloma.
Kappa CD28 T cells

B Cell Lymphoma, or Chronic Lymphocytic Leukemia Clinical Trial using CD19CAR-28-zeta T cells; Ipilimumab

Baylor College of Medicine - Recruiting N/A or older.
- Phase I Study Of CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, Acute Lymphocytic Leukemia, and Chronic Lymphocytic Leukemia.
CD19CAR-28-zeta T cells; Ipilimumab

Infection, or Leukemia Clinical Trial using alemtuzumab; polymerase chain reaction; flow cytometry; laboratory biomarker analysis; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Consolidation Therapy With Alemtuzumab (MabCampathr) in Patients With Chronic Lymphocytic Leukemia Who Are in Complete or Partial 2nd Remission After Cytoreduction With Fludarabine or Fludarabine Plus Cyclophosphamide or Fludarabine Plus Cyclophosphamide Plus Rituximab or Bendamustine or Bendamustine Plus Rituximab - a Phase I/II Study.
alemtuzumab; polymerase chain reaction; flow cytometry; laboratory biomarker analysis; pharmacological study

B-cell Chronic Lymphocytic Leukemia, Hematopoietic/Lymphoid Cance Clinical Trial using carfilzomib; Cytokine Assessment; Pharmacodynamic Studies; Proteosome Inhibition Assessment; Pharmacogenomic Studies

Ohio State University Comprehensive Cancer Center - Recruiting 18 years or older.
- A Phase I Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)/Prolymphocytic Leukemia (PLL).
carfilzomib; Cytokine Assessment; Pharmacodynamic Studies; Proteosome Inhibition Assessment; Pharmacogenomic Studies

Leukemia, Myeloid, Chronic, AML, Leukemia, Lymphocytic, Acute, MD Clinical Trial using Stem Cell Transplant; Cyclophosphamide; Total Body Irradiation; Busulfan

Masonic Cancer Center, University of Minnesota - Recruiting N/A to 55 years.
- Allogeneic Transplant for Hematological Malignancy.
Stem Cell Transplant; Cyclophosphamide; Total Body Irradiation; Busulfan

Chronic Lymphocytic Leukemia Stage A(0), Chronic Lymphocytic Leuk Clinical Trial

Gruppo Italiano Studio Linfomi - Recruiting 18 years to 80 years.
- Prospective Collection of Biological Data of Prognostic Relevance in Patients.

Leukemia, or Lymphoma Clinical Trial using anti-thymocyte globulin; rituximab; busulfan; cyclophosphamide; fludarabine phosphate; methotrexate; sirolimus; tacrolimus; laboratory biomarker analysis; nonmyeloablative allogeneic hematopoietic stem cell transplantation; peripheral blood stem cell transplantation

National Cancer Institute (NCI) - Recruiting 18 years to 69 years.
- Phase II Study of Reduced-Intensity Allogeneic Stem Cell Transplant for High-Risk Chronic Lymphocytic Leukemia (CLL).
anti-thymocyte globulin; rituximab; busulfan; cyclophosphamide; fludarabine phosphate; methotrexate; sirolimus; tacrolimus; laboratory biomarker analysis; nonmyeloablative allogeneic hematopoietic stem cell transplantation; peripheral blood stem cell transplantation

Chronic Lymphocytic Leukemia Clinical Trial using Ofatumumab

Grupo Espanol de trasplantes hematopoyeticos y terapia celular - Recruiting 18 years to 70 years.
- Ofatumumab as Part of the Reduced Intensity Conditioning Regimen for Patients With High Risk Chronic Lymphocytic Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation: a Pilot Study by GETH and GELLC.
Ofatumumab